Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer - PubMed

Affiliations

• PMID: 22514107
• DOI: 10.1002/ijc.27605

Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer

Gordana Halec et al. Int J Cancer. 2013.

Abstract

Judging the carcinogenicity of human papillomavirus (HPV) types rarely found in cervical cancer (CxCa) is hindered by lack of studies of their biological activity in cancer tissues. To asses transcriptional activity of HPV types, we have developed ultra-short amplimer, splice-site specific, E6*I mRNA RT-PCR assays for 12 high-risk (HR)-HPV (IARC Group 1) and eight probable/possible high-risk (pHR)-HPV types (IARC Group 2A/B carcinogens). Previously unreported E6*I splice sites of the six pHR-HPV types 26, 53, 67, 70, 73 and 82 were identified by cloning and sequencing. We analyzed 97 formalin-fixed paraffin-embedded (FFPE) Mongolian CxCa biopsies for presence of HPV DNA by two sensitive genotyping assays, for E6*I transcripts of all HR-/pHR-HPV types identified and for expression of HPV surrogate markers p16(INK4a), pRb and p53. E6*I of at least one HR-/pHR-HPV was expressed in 94 (98%) of cancer tissues including seven with pHR-HPV types 26, 66, 70 or 82 as single transcribed types. Fifty-eight of E6*I mRNA transcribing cases were analyzable by immunohistochemistry and displayed p16(INK4a) overexpression in 57 (98%), pRb downregulation in 56 (97%) and p53 downregulation in 36 (62%) tissues. The newly developed E6*I mRNA RT-PCR assays appeared to be highly sensitive method to analyze HPV transcription in FFPE materials. Our finding of viral oncogene transcription of pHR-HPV types 26, 66, 70 and 82 in cervical tumors, in the absence of any other transcriptionally active HR-type and with p16(INK4a) overexpression and pRb downregulation, may support a reassessment of the carcinogenicity classification of these pHR-HPV types.

Similar articles

• Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.

  Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M; Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group. Halec G, et al. J Pathol. 2014 Dec;234(4):441-51. doi: 10.1002/path.4405. Epub 2014 Sep 12. J Pathol. 2014. PMID: 25043390

• Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.

  Kanao H, Enomoto T, Ueda Y, Fujita M, Nakashima R, Ueno Y, Miyatake T, Yoshizaki T, Buzard GS, Kimura T, Yoshino K, Murata Y. Kanao H, et al. Cancer Lett. 2004 Sep 15;213(1):31-7. doi: 10.1016/j.canlet.2004.03.030. Cancer Lett. 2004. PMID: 15312681

• Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a.

  Andersson S, Hansson B, Norman I, Gaberi V, Mints M, Hjerpe A, Karlsen F, Johansson B. Andersson S, et al. Int J Oncol. 2006 Sep;29(3):705-11. Int J Oncol. 2006. PMID: 16865288

• Diagnostic accuracy of p16^INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.

  Prigge ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M. Prigge ES, et al. Int J Cancer. 2017 Mar 1;140(5):1186-1198. doi: 10.1002/ijc.30516. Epub 2016 Dec 2. Int J Cancer. 2017. PMID: 27859245 Review.

• Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

  Cuschieri K, Wentzensen N. Cuschieri K, et al. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45. doi: 10.1158/1055-9965.EPI-08-0306. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18842994 Free PMC article. Review.

Cited by

• Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor.

  Hoffmann M, Quabius ES, Tribius S, Hebebrand L, Görögh T, Halec G, Kahn T, Hedderich J, Röcken C, Haag J, Waterboer T, Schmitt M, Giuliano AR, Kast WM. Hoffmann M, et al. Oncol Rep. 2013 May;29(5):1962-8. doi: 10.3892/or.2013.2327. Epub 2013 Mar 5. Oncol Rep. 2013. PMID: 23467841 Free PMC article.

• Tracing human papillomavirus in skin and mucosal squamous cell carcinoma: a histopathological retrospective survey.

  Nili A, Daneshpazhooh M, Mahmoudi H, Kamyab K, Jamshidi ST, Soleiman-Meigooni S, Darvishi M. Nili A, et al. Dermatol Reports. 2024 Feb 1;16(2):9833. doi: 10.4081/dr.2024.9833. eCollection 2024 Jun 14. Dermatol Reports. 2024. PMID: 38979521 Free PMC article.

• Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.

  Ährlund-Richter A, Cheng L, Hu YOO, Svensson M, Pennhag AAL, Ursu RG, Haeggblom L, Grün N, Ramqvist T, Engstrand L, Dalianis T, Du J. Ährlund-Richter A, et al. Front Cell Infect Microbiol. 2019 Mar 20;9:59. doi: 10.3389/fcimb.2019.00059. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 30949454 Free PMC article.

• Periodontitis and oral human papillomavirus infection among Hispanic adults.

  Ortiz AP, González D, Vivaldi-Oliver J, Castañeda M, Rivera V, Díaz E, Centeno H, Muñoz C, Palefsky J, Joshipura K, Pérez CM. Ortiz AP, et al. Papillomavirus Res. 2018 Jun;5:128-133. doi: 10.1016/j.pvr.2018.03.003. Epub 2018 Mar 16. Papillomavirus Res. 2018. PMID: 29555599 Free PMC article.

• Preferential Tissue Sites of Different Cancer-Risk Groups of Human Papillomaviruses.

  Okodo M, Okayama K, Sasagawa T, Teruya K, Settsu R, Mizuno S, Ishii Y, Oda M. Okodo M, et al. Int J Mol Sci. 2023 Aug 24;24(17):13151. doi: 10.3390/ijms241713151. Int J Mol Sci. 2023. PMID: 37685959 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal